Human-centered risk management for medical devices - new methods and tools

被引:6
|
作者
Janss, Armin [1 ]
Plogmann, Simon [1 ]
Radermacher, Klaus [1 ]
机构
[1] Rhein Westfal TH Aachen, Helmholtz Inst BME, Chair Med Engn, Aachen, Germany
来源
BIOMEDICAL ENGINEERING-BIOMEDIZINISCHE TECHNIK | 2016年 / 61卷 / 02期
关键词
human-machine interaction; human-risk analysis; human-risk control; human errors; human error taxonomy; human factors; medical devices; model-based usability evaluation; COUNTERMEASURE; RELIABILITY; TECHNOLOGY; SELECTION;
D O I
10.1515/bmt-2014-0124
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Studies regarding adverse events with technical devices in the medical context showed, that in most of the cases non-usable interfaces are the cause for use deficiencies and therefore a potential harm for the patient and third parties. This is partially due to the lack of suitable methods for interlinking usability engineering and human-centered risk management. Especially regarding the early identification of human-induced errors and the systematic control of these failures, medical device manufacturers and in particular the developers have to be supported in order to guarantee reliable design and error-tolerant human-machine interfaces (HMI). In this context, we developed the HiFEM methodology and a corresponding software tool (mAIXuse) for model-based human risk analysis. Based on a two-fold approach, HiFEM provides a task-type-sensitive modeling structure with integrated temporal relations in order to represent and analyze the use process in a detailed way. The approach can be used from early developmental stages up to the validation process. Results of a comparative study with the HiFEM method and a classical process-failure mode and effect analysis (FMEA) depict, that the new modeling and analysis technique clearly outperforms the FMEA. Besides, we implemented a new method for systematic human risk control (mAIXcontrol). Accessing information from the method's knowledge base enables the operator to detect the most suitable countermeasures for a respective risk. Forty-one approved generic countermeasure principles have been indexed as a resulting combination of root causes and failures in a matrix. The methodology has been tested in comparison to a conventional approach as well. Evaluation of the matrix and the reassessment of the risk priority numbers by a blind expert demonstrate a substantial benefit of the new mAIXcontrol method.
引用
收藏
页码:165 / 181
页数:17
相关论文
共 36 条
  • [31] Towards Customer-Centric Additive Manufacturing: Making Human-Centered 3D Design Tools through a Handheld-Based Multi-Touch User Interface
    Rodriguez-Conde, Ivan
    Campos, Celso
    SENSORS, 2020, 20 (15) : 1 - 28
  • [32] Outsourcing the Management of Reusable Medical Devices in a Chain-Wide Care Setting: Mixed Methods Feasibility Study
    Noort, Bart A. C.
    Buijs, Paul
    Roemeling, Oskar
    INTERACTIVE JOURNAL OF MEDICAL RESEARCH, 2023, 12
  • [33] The integrated prospect theory with consensus model for risk analysis of human error factors in the clinical use of medical devices
    Zheng, Qiaohong
    Liu, Xinwang
    Wang, Weizhong
    Wu, Qun
    Deveci, Muhammet
    Pamucar, Dragan
    EXPERT SYSTEMS WITH APPLICATIONS, 2023, 217
  • [34] Benefit Assessment for Examination and Treatment Methods with Medical Devices of High Risk: Trade-off between Patient Benefit, Evidence and Access
    Muehlbacher, Axel C.
    Juhnke, Christin
    GESUNDHEITSWESEN, 2018, 80 : S80 - S87
  • [35] KEY ASPECTS TO IMPLEMENT A MEDICAL DEVICES SURVEILLANCE PLAN IN HEALTH CARE INSTITUTIONS AND BRIEF OVERVIEW OF THIS PROCESS ENHANCEMENT THROUGH RISK MANAGEMENT
    Alvarez, Alessa I.
    Roldan, Sebastian
    2013 PAN AMERICAN HEALTH CARE EXCHANGES (PAHCE), 2013,
  • [36] Pain assessment and management in children in the postoperative period: A review of the most commonly used postoperative pain assessment tools, new diagnostic methods and the latest guidelines for postoperative pain therapy in children
    Zielinski, Jakub
    Morawska-Kochman, Monika
    Zatonski, Tomasz
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 29 (03): : 365 - 374